JP2005523295A - 難溶性薬剤の自己乳化型薬物送達システム - Google Patents

難溶性薬剤の自己乳化型薬物送達システム Download PDF

Info

Publication number
JP2005523295A
JP2005523295A JP2003572547A JP2003572547A JP2005523295A JP 2005523295 A JP2005523295 A JP 2005523295A JP 2003572547 A JP2003572547 A JP 2003572547A JP 2003572547 A JP2003572547 A JP 2003572547A JP 2005523295 A JP2005523295 A JP 2005523295A
Authority
JP
Japan
Prior art keywords
paclitaxel
pharmaceutical composition
composition according
sedds
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003572547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523295A5 (enExample
Inventor
グレゴリー、ランベール
アラン、ラザフィンドラツィータ
ジャン‐セバスティアン、ガリグ
シチェン、ヤン
ネスリハン、グルソイ
サイモン、ベニータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novagali SA
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Novagali SA
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02290513A external-priority patent/EP1340497A1/en
Application filed by Novagali SA, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Novagali SA
Publication of JP2005523295A publication Critical patent/JP2005523295A/ja
Publication of JP2005523295A5 publication Critical patent/JP2005523295A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cash Registers Or Receiving Machines (AREA)
JP2003572547A 2002-03-01 2003-02-28 難溶性薬剤の自己乳化型薬物送達システム Pending JP2005523295A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36109002P 2002-03-01 2002-03-01
EP02290513A EP1340497A1 (en) 2002-03-01 2002-03-01 Self emulsifying drug delivery systems for poorly soluble drugs
PCT/IB2003/001336 WO2003074027A2 (en) 2002-03-01 2003-02-28 Self emulsifying drug delivery systems for poorly soluble drugs

Publications (2)

Publication Number Publication Date
JP2005523295A true JP2005523295A (ja) 2005-08-04
JP2005523295A5 JP2005523295A5 (enExample) 2006-03-02

Family

ID=27790109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003572547A Pending JP2005523295A (ja) 2002-03-01 2003-02-28 難溶性薬剤の自己乳化型薬物送達システム

Country Status (10)

Country Link
US (1) US20050232952A1 (enExample)
EP (1) EP1480636B1 (enExample)
JP (1) JP2005523295A (enExample)
AT (1) ATE359779T1 (enExample)
AU (1) AU2003214538A1 (enExample)
CA (1) CA2478424A1 (enExample)
DE (1) DE60313299T2 (enExample)
ES (1) ES2283756T3 (enExample)
IL (1) IL163808A0 (enExample)
WO (1) WO2003074027A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013180253A1 (ja) * 2012-05-31 2016-01-21 テルモ株式会社 ｐＨ感受性担体およびその製造方法、並びに該担体を含むｐＨ感受性医薬、ｐＨ感受性医薬組成物およびこれを用いた培養方法

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511475A (ja) 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
WO2008042841A2 (en) * 2006-10-02 2008-04-10 Dr. Reddy's Laboratories Limited Docetaxel compositions
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2262369A4 (en) * 2008-04-04 2013-05-29 Robert Shorr LIPID-OIL-WATER-NANOEMULSION-DELIVERY SYSTEM FOR ACTIVE SUBSTANCES WITH MICROTUBULI INTERACTION
US8541465B2 (en) 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
RU2603833C2 (ru) 2010-11-08 2016-11-27 Кадила Фармасьютикалз Лимитед Фармацевтическая композиция таксоидов
EP3424493A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CN109589305B (zh) * 2018-12-03 2021-03-19 昆明积大制药股份有限公司 多西他赛-环孢素a共包载自乳化制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025620A1 (en) * 1996-12-11 1998-06-18 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
WO1999006024A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
WO2000050007A1 (en) * 1999-02-26 2000-08-31 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic therapeutic agents
JP2001508445A (ja) * 1997-01-07 2001-06-26 ソーナス ファーマシューティカルズ，インコーポレーテッド 溶解性に劣る薬物のためのエマルジョンビヒクル
WO2001068139A1 (en) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilizing water-insoluble agents and preparation method thereof
JP2001524988A (ja) * 1998-03-10 2001-12-04 ナプロ バイオセラピューティクス インク． タキサン（ｔａｘａｎｅ）を輸送するための方法および組成物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0656779B1 (en) * 1992-08-28 2000-04-12 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5627209A (en) * 1993-12-15 1997-05-06 Alcon Laboratories, Inc. Use of certain 9-haloprostaglandins to treat glaucoma and ocular hypertension
US5612039A (en) * 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
US5567424A (en) * 1994-06-10 1996-10-22 Reliv International, Inc. Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
WO1996036585A1 (en) * 1995-05-15 1996-11-21 Sabinsa Corporation A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy citric acid
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
IT1276253B1 (it) * 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
US5716976A (en) * 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
US6160172A (en) * 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
AU5802499A (en) * 1998-09-01 2000-03-21 Amway Corporation Diet composition and method of weight management
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
US6447807B1 (en) * 1999-09-14 2002-09-10 Dallas L. Clouatre Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
US6399089B1 (en) * 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US6383482B1 (en) * 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
US6579866B2 (en) * 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
US6476071B1 (en) * 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6482858B1 (en) * 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6441041B1 (en) * 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US6638542B2 (en) * 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
US7119110B2 (en) * 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
US7507421B2 (en) * 2002-04-30 2009-03-24 Unibar Corporation Hydroxycitric acid salt composition and method of making
US20040186181A1 (en) * 2003-03-21 2004-09-23 Interhealth Nutraceuticals, Incorporated Method and composition for decreasing ghrelin levels

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025620A1 (en) * 1996-12-11 1998-06-18 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
JP2001508445A (ja) * 1997-01-07 2001-06-26 ソーナス ファーマシューティカルズ，インコーポレーテッド 溶解性に劣る薬物のためのエマルジョンビヒクル
WO1999006024A1 (en) * 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
JP2001524988A (ja) * 1998-03-10 2001-12-04 ナプロ バイオセラピューティクス インク． タキサン（ｔａｘａｎｅ）を輸送するための方法および組成物
WO2000050007A1 (en) * 1999-02-26 2000-08-31 Lipocine, Inc. Compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001068139A1 (en) * 2000-03-13 2001-09-20 Korea Institute Of Science And Technology Formulation solubilizing water-insoluble agents and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013180253A1 (ja) * 2012-05-31 2016-01-21 テルモ株式会社 ｐＨ感受性担体およびその製造方法、並びに該担体を含むｐＨ感受性医薬、ｐＨ感受性医薬組成物およびこれを用いた培養方法
US10765751B2 (en) 2012-05-31 2020-09-08 Terumo Kabushiki Kaisha pH sensitive carrier and preparation method thereof, and pH sensitive drug and pH sensitive drug composition each containing the carrier, and method for treating or preventing diseases using the same

Also Published As

Publication number Publication date
US20050232952A1 (en) 2005-10-20
WO2003074027A8 (en) 2004-10-07
CA2478424A1 (en) 2003-09-12
EP1480636A2 (en) 2004-12-01
DE60313299D1 (de) 2007-05-31
ES2283756T3 (es) 2007-11-01
WO2003074027A2 (en) 2003-09-12
DE60313299T2 (de) 2008-01-03
AU2003214538A1 (en) 2003-09-16
WO2003074027A3 (en) 2003-12-18
EP1480636B1 (en) 2007-04-18
IL163808A0 (en) 2005-12-18
ATE359779T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
EP1480636B1 (en) Self emulsifying drug delivery systems for taxoids
EP1658050B1 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
Constantinides et al. Tocol emulsions for drug solubilization and parenteral delivery
KR100533458B1 (ko) 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
US6964946B1 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CA2710525C (en) Nanodispersion
KR20050095826A (ko) 약리학적 물질의 조성물 및 그 전달방법
Thakkar Influence of excipients on drug absorption via modulation of intestinal transporters activity
AU2011327824B2 (en) Pharmaceutical composition of taxoids
US20060292186A1 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
JP2009513557A (ja) タキソイドの経口投与用自己乳化および自己ミクロ乳化製剤
EP1340497A1 (en) Self emulsifying drug delivery systems for poorly soluble drugs
Elhissi et al. Taxane anticancer formulations: challenges and achievements
Yin et al. Improved solubility of docetaxel using a microemulsion delivery system: formulation optimization and evaluation
Elhissi et al. Taxane formulations: from plant to clinic
RU2236226C2 (ru) Пероральные фармацевтические композиции, содержащие таксаны, и способы лечения с их применением
HK1074006A (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20060024341A1 (en) Microemulsion composition and related method
Bansal PEGylated methotrexate based micellar conjugates for anticancer chemotherapy
HK1256760B (en) Oral taxane compositions and methods
HK1256760A1 (en) Oral taxane compositions and methods
HK1091743B (en) Semi-solid formulations for the oral administration of taxoids
HK1091743A1 (zh) 用於口服施用紫杉烷类的半固体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100326